Abstract Number: 1434 • 2013 ACR/ARHP Annual Meeting
Assessing Janus Kinase inhibitor’s Place In Therapy In Established Rheumatoid Arthritis Patients – From a Simplified Indirect Comparison Versus Tumor Necrosis Factor Inhibitors To a Bayesian Probability Of Response – The Value Of Transparency
Background/Purpose: Bayesian style network meta-analyses and mixed treatment comparisons help address potential bias from effect modifying trial covariates within indirect comparisons and are theoretically easier…Abstract Number: 822 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Casein Kinase II Reduces TGFβ Induced Fibroblast Activation and Ameliorates Experimental Fibrosis
Background/Purpose: Casein kinase-2 (CK2) is a highly conserved serine/threonine kinase. CK2 is a tetramer composed of 2 catalytic subunits (α or α’) and 2 β…Abstract Number: 2490 • 2012 ACR/ARHP Annual Meeting
Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
Background/Purpose: Patients (pts) with RA are at increased risk for herpes zoster (HZ) i.e. ‘shingles'. Tofacitinib, a novel oral Janus kinase inhibitor investigated as a…Abstract Number: 310 • 2012 ACR/ARHP Annual Meeting
STAT3 Plays a Central Role in NLRP3 Inflammasome-Mediated IL-1β Production and Pyronecrosis
Background/Purpose: Gain of function mutations in NLRP3 cause cryopyrin-associated periodic fever syndromes (CAPS), the most severe form of which is neonatal-onset multisystem inflammatory disease (NOMID),…Abstract Number: 2485 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor: Analyses of Efficacy and Safety of 10 versus 5mg Twice Daily in a Pooled Phase 3 and Long-Term Extension Rheumatoid Arthritis Population
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Phase (P) 3 studies demonstrated…Abstract Number: 2326 • 2012 ACR/ARHP Annual Meeting
Discovery of a Highly Potent, Selective Reversible Covalent Inhibitor of JAK3 Kinase
Background/Purpose: Targeting of the JAK-STAT pathway has been shown to be efficacious for treatment of patients with rheumatoid arthritis through the successful use of pan-JAK…Abstract Number: 2150 • 2012 ACR/ARHP Annual Meeting
Action of Tofacitinib Via Human Dendritic Cells
Background/Purpose: Tofacitinib, an oral Janus Kinase (JAK) inhibitor, has gathered attention in treatment of Rheumatoid arthritis (RA). Although JAKs are well known for its importance…Abstract Number: 2084 • 2012 ACR/ARHP Annual Meeting
ASP015K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats
Background/Purpose: The Janus kinase (JAK) family of enzymes plays a key role in cytokine signaling, which is involved in the pathogenic events of immune-mediated disorders…Abstract Number: 1697 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials
Background/Purpose: Patients with rheumatoid arthritis (RA) experience adverse events (AEs) attributed to both the disease and its treatment. Tofacitinib is a novel oral Janus kinase…Abstract Number: 1322 • 2012 ACR/ARHP Annual Meeting
Coadministration of ASP015K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis
Background/Purpose: ASP015K is an oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3 in development for treatment of rheumatoid arthritis (RA) and other autoimmune diseases.…Abstract Number: 1297 • 2012 ACR/ARHP Annual Meeting
Tofacitinib and Adalimumab Achieve Similar Rates of Low Disease Activity in Rheumatoid Arthritis — Lack of Improvement in Disease Activity Score by 3 Months Predicts Low Likelihood of Low Disease Activity At 1 Year
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This post-hoc analysis of the…Abstract Number: 1277 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This 24‑month (Mo) Phase 3…Abstract Number: 1278 • 2012 ACR/ARHP Annual Meeting
Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
Background/Purpose: Biologic therapies that block tumor necrosis factor-alpha (TNF) increase the risk of tuberculosis (TB), and screening for latent tuberculosis infection (LTBI) before their initiation…Abstract Number: 1282 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy in RA. Here we report the safety…Abstract Number: 1283 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate: Results of Two Phase 3 Studies
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. The efficacy and safety of…
ACR Meeting Abstracts